ring finger protein 14Genealiases: ARA54 · HFB30 · HRIHFB2038 · TRIAD2
Q-omics provides the consensus-scored RNF14 profile across patient tissues and cancer cell-line models. RNF14 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNF14 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, RNF14 protein abundance shows 20,301 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, LIHC, and LUAD as cancer lineages where RNF14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF14 survival associations across molecular data types. RNF14 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF14 RNA expression–survival associations across cancer types. High RNF14 expression shows unfavorable associations in HNSC, SCLC, CESC, LGG and UVM, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RNF14 RNA expression.
This table summarizes RNF14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RNF14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF14 shows lower tumor expression in THCA, LUSC and BLCA and higher tumor expression in LIHC, KIRC and HNSC. The LIHC box plot shows higher RNF14 RNA expression in tumor versus normal tissue (log2 FC = +1.043, t-test p < 0.001).
This table shows molecular features associated with RNF14 in patient tissues and cancer cell lines. In patient samples, RNF14 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
